New Four-Drug attack on stubborn blood cancer
NCT ID NCT07150104
Summary
This early-stage trial is testing a combination of four different drugs for people with multiple myeloma that has come back or stopped responding to other treatments. The main goals are to find a safe dose and see how well the body tolerates the combination. It will involve a small group of participants to check for side effects before potentially testing it in more people.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Salvador, Estado de Bahia, 41253-190, Brazil
-
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, 90110-270, Brazil
-
GSK Investigational Site
Halifax, Nova Scotia, B3H 1V7, Canada
-
GSK Investigational Site
Villejuif, 94805, France
-
GSK Investigational Site
Mexico City, 01330, Mexico
-
GSK Investigational Site
Oslo, 0450, Norway
-
GSK Investigational Site
Lublin, 20-081, Poland
-
GSK Investigational Site
Seoul, 03080, South Korea
-
GSK Investigational Site
Ulsan, 44033, South Korea
-
GSK Investigational Site
Falun, SE-791 82, Sweden
Conditions
Explore the condition pages connected to this study.